The University of Chicago Header Logo

Connection

Mark J. Ratain to Metabolic Clearance Rate

This is a "connection" page, showing publications Mark J. Ratain has written about Metabolic Clearance Rate.
Connection Strength

0.780
  1. Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors. Clin Pharmacol Ther. 2018 06; 103(6):956-958.
    View in: PubMed
    Score: 0.158
  2. Individualizing dosing of irinotecan. Clin Cancer Res. 2010 Jan 15; 16(2):371-2.
    View in: PubMed
    Score: 0.091
  3. Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther. 2008 Sep; 84(3):393-402.
    View in: PubMed
    Score: 0.081
  4. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res. 2004 Dec 15; 10(24):8325-31.
    View in: PubMed
    Score: 0.064
  5. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11.
    View in: PubMed
    Score: 0.064
  6. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. Clin Cancer Res. 1999 Jun; 5(6):1325-30.
    View in: PubMed
    Score: 0.044
  7. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol. 1997; 39(5):440-4.
    View in: PubMed
    Score: 0.037
  8. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7.
    View in: PubMed
    Score: 0.033
  9. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol. 2014 Nov; 78(5):1005-13.
    View in: PubMed
    Score: 0.032
  10. Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol. 2014 Nov; 74(5):927-38.
    View in: PubMed
    Score: 0.031
  11. Conventional dosing of anticancer agents: precisely wrong or just inaccurate? Clin Pharmacol Ther. 2014 Apr; 95(4):361-4.
    View in: PubMed
    Score: 0.031
  12. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res. 2014 Apr 15; 20(8):2205-14.
    View in: PubMed
    Score: 0.030
  13. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan; 23(1):29-33.
    View in: PubMed
    Score: 0.028
  14. Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther. 1987 Jan; 41(1):61-7.
    View in: PubMed
    Score: 0.019
  15. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer. Cancer Res. 1986 Aug; 46(8):4184-8.
    View in: PubMed
    Score: 0.018
  16. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol. 2002 Aug; 50(2):121-6.
    View in: PubMed
    Score: 0.014
  17. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther. 1989 Apr; 45(4):340-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.